Liver resection and ablation for squamous cell carcinoma liver metastases.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
received:
22
03
2021
accepted:
17
05
2021
entrez:
24
8
2021
pubmed:
25
8
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). Members of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.
Sections du résumé
BACKGROUND
Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS).
METHOD
Members of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS.
RESULTS
Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30).
CONCLUSION
Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.
Identifiants
pubmed: 34426830
pii: 6356812
doi: 10.1093/bjsopen/zrab060
pmc: PMC8382975
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
World J Surg. 2018 Apr;42(4):1073-1084
pubmed: 28875334
Gastroenterol Res Pract. 2017;2017:5184146
pubmed: 28811821
Dis Colon Rectum. 2017 Aug;60(8):785-791
pubmed: 28682963
Acta Otorhinolaryngol Ital. 2020 Apr;40(SUPPL. 1):S1-S86
pubmed: 32469009
Am J Surg. 2018 Jan;215(1):125-130
pubmed: 29061283
Eur Arch Otorhinolaryngol. 2018 May;275(5):1239-1247
pubmed: 29520497
Oncotarget. 2014 Nov 30;5(22):11133-42
pubmed: 25373735
BMC Surg. 2018 Oct 29;18(1):89
pubmed: 30373582
J Surg Oncol. 2019 Mar;119(4):489-496
pubmed: 30636052
J Hepatobiliary Pancreat Sci. 2018 Nov;25(11):465-475
pubmed: 30311741
Crit Rev Oncol Hematol. 2014 Jul;91(1):47-63
pubmed: 24556572
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Eur J Cancer. 2017 Oct;84:130-140
pubmed: 28802709
J Gastrointest Surg. 2016 Jun;20(6):1163-72
pubmed: 26921025
World J Surg Oncol. 2019 Sep 4;17(1):156
pubmed: 31484583
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg. 2006 Oct;244(4):524-35
pubmed: 16998361
Br J Surg. 2018 Nov;105(12):1665-1670
pubmed: 29893476
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861604
Eur J Surg Oncol. 2017 Nov;43(11):2129-2134
pubmed: 28958732
Ann Surg Oncol. 2007 Oct;14(10):2807-16
pubmed: 17551795
J Am Coll Surg. 2012 May;214(5):769-77
pubmed: 22425166
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1083-92
pubmed: 26242369
Br J Cancer. 2010 Mar 30;102(7):1123-8
pubmed: 20354531